Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 73

1.

Elevated HOX gene expression in acute myeloid leukemia is associated with NPM1 mutations and poor survival.

Nagy Á, Ősz Á, Budczies J, Krizsán S, Szombath G, Demeter J, Bödör C, Győrffy B.

J Adv Res. 2019 Jun 11;20:105-116. doi: 10.1016/j.jare.2019.05.006. eCollection 2019 Nov.

2.

Dissection of subclonal evolution by temporal mutation profiling in chronic lymphocytic leukemia patients treated with ibrutinib.

Gángó A, Alpár D, Galik B, Marosvári D, Kiss R, Fésüs V, Aczél D, Eyüpoglu E, Nagy N, Nagy Á, Krizsán S, Reiniger L, Farkas P, Kozma A, Ádám E, Tasnády S, Réti M, Matolcsy A, Gyenesei A, Mátrai Z, Bödör C.

Int J Cancer. 2019 Jun 10. doi: 10.1002/ijc.32502. [Epub ahead of print]

PMID:
31180577
3.

Calreticulin mutation specific CAL2 immunohistochemistry accurately identifies rare calreticulin mutations in myeloproliferative neoplasms.

Mózes R, Gángó A, Sulák A, Vida L, Reiniger L, Timár B, Krenács T, Alizadeh H, Masszi T, Gaál-Weisinger J, Demeter J, Csomor J, Matolcsy A, Kajtár B, Bödör C.

Pathology. 2019 Apr;51(3):301-307. doi: 10.1016/j.pathol.2018.11.007. Epub 2018 Dec 31.

PMID:
30606612
4.

[Change in paradigm in the treatment of pediatric acquired bone marrow failure syndromes in Hungary].

Kállay K, Csomor J, Ádám E, Bödör C, Kassa C, Simon R, Kovács G, Péter G, Ottóffy G, Bartyik K, Kiss C, Masát P, Réti M, Tóth B, Kriván G.

Orv Hetil. 2018 Oct;159(42):1710-1719. doi: 10.1556/650.2018.31171. Hungarian.

PMID:
30334483
5.

Spatial clonal evolution leading to ibrutinib resistance and disease progression in chronic lymphocytic leukemia.

Kiss R, Alpár D, Gángó A, Nagy N, Eyupoglu E, Aczél D, Matolcsy A, Csomor J, Mátrai Z, Bödör C.

Haematologica. 2019 Jan;104(1):e38-e41. doi: 10.3324/haematol.2018.202085. Epub 2018 Sep 27. No abstract available.

6.

High-Throughput Copy Number Profiling by Digital Multiplex Ligation-Dependent Probe Amplification in Multiple Myeloma.

Kosztolányi S, Kiss R, Atanesyan L, Gángó A, de Groot K, Steenkamer M, Jáksó P, Matolcsy A, Kajtár B, Pajor L, Szuhai K, Savola S, Bödör C, Alpár D.

J Mol Diagn. 2018 Nov;20(6):777-788. doi: 10.1016/j.jmoldx.2018.06.004. Epub 2018 Aug 8.

PMID:
30096382
7.

EZH2 is upregulated in the proliferation centers of CLL/SLL lymph nodes.

Szurián K, Csala I, Marosvári D, Rajnai H, Dezső K, Bödör C, Piurkó V, Matolcsy A, Reiniger L.

Exp Mol Pathol. 2018 Oct;105(2):161-165. doi: 10.1016/j.yexmp.2018.07.009. Epub 2018 Jul 18.

PMID:
30031020
8.

Concomitant 1p36 deletion and TNFRSF14 mutations in primary cutaneous follicle center lymphoma frequently expressing high levels of EZH2 protein.

Gángó A, Bátai B, Varga M, Kapczár D, Papp G, Marschalkó M, Kuroli E, Schneider T, Csomor J, Matolcsy A, Bödör C, Szepesi Á.

Virchows Arch. 2018 Oct;473(4):453-462. doi: 10.1007/s00428-018-2384-3. Epub 2018 Jun 1.

PMID:
29858685
9.

GATA2 monoallelic expression underlies reduced penetrance in inherited GATA2-mutated MDS/AML.

Al Seraihi AF, Rio-Machin A, Tawana K, Bödör C, Wang J, Nagano A, Heward JA, Iqbal S, Best S, Lea N, McLornan D, Kozyra EJ, Wlodarski MW, Niemeyer CM, Scott H, Hahn C, Ellison A, Tummala H, Cardoso SR, Vulliamy T, Dokal I, Butler T, Smith M, Cavenagh J, Fitzgibbon J.

Leukemia. 2018 Nov;32(11):2502-2507. doi: 10.1038/s41375-018-0134-9. Epub 2018 Apr 19. No abstract available.

10.

[Multiplex ligation-dependent probe amplification in oncohematological diagnostics and research].

Kiss R, Kosztolányi S, Gángó A, Szuhai K, Bödör C, Alpár D.

Orv Hetil. 2018 Apr;159(15):583-592. doi: 10.1556/650.2018.31053. Hungarian.

PMID:
29631426
11.

Discrepancy Between Low Levels of mTOR Activity and High Levels of P-S6 in Primary Central Nervous System Lymphoma May Be Explained by PAS Domain-Containing Serine/Threonine-Protein Kinase-Mediated Phosphorylation.

Marosvári D, Nagy N, Kriston C, Deák B, Hajdu M, Bödör C, Csala I, Bagó AG, Szállási Z, Sebestyén A, Reiniger L.

J Neuropathol Exp Neurol. 2018 Apr 1;77(4):268-273. doi: 10.1093/jnen/nlx121.

PMID:
29361117
12.

Quantitative assessment of JAK2 V617F and CALR mutations in Philadelphia negative myeloproliferative neoplasms.

Gángó A, Mózes R, Boha Z, Kajtár B, Timár B, Király PA, Kiss R, Fésüs V, Nagy N, Demeter J, Körösmezey G, Borbényi Z, Marton I, Szőke A, Masszi T, Farkas P, Várkonyi J, Plander M, Pósfai É, Egyed M, Pál K, Radványi G, Hamed A, Csomor J, Matolcsy A, Alpár D, Bödör C.

Leuk Res. 2018 Feb;65:42-48. doi: 10.1016/j.leukres.2017.12.005. Epub 2018 Jan 2.

PMID:
29306106
13.

[State of the art molecular diagnostics and therapy of chronic lymphocytic leukaemia in the era of new targeted therapies].

Gurbity Pálfi T, Fésüs V, Bödör C, Borbényi Z.

Orv Hetil. 2017 Oct;158(41):1620-1629. doi: 10.1556/650.2017.30870. Review. Hungarian.

PMID:
29025288
14.

Functional studies of chronic lymphocytic leukemia B cells expressing β2-integrin type complement receptors CR3 and CR4.

Uzonyi B, Mácsik-Valent B, Lukácsi S, Kiss R, Török K, Kremlitzka M, Bajtay Z, Demeter J, Bödör C, Erdei A.

Immunol Lett. 2017 Sep;189:73-81. doi: 10.1016/j.imlet.2017.05.016. Epub 2017 May 31.

PMID:
28577901
15.

Recurrent somatic JAK-STAT pathway variants within a RUNX1-mutated pedigree.

Tawana K, Wang J, Király PA, Kállay K, Benyó G, Zombori M, Csomor J, Al Seraihi A, Rio-Machin A, Matolcsy A, Chelala C, Cavenagh J, Fitzgibbon J, Bödör C.

Eur J Hum Genet. 2017 Aug;25(8):1020-1024. doi: 10.1038/ejhg.2017.80. Epub 2017 May 17.

16.

Familial Acute Myeloid Leukemia and Myelodysplasia in Hungary.

Király AP, Kállay K, Gángó A, Kellner Á, Egyed M, Szőke A, Kiss R, Vályi-Nagy I, Csomor J, Matolcsy A, Bödör C.

Pathol Oncol Res. 2018 Jan;24(1):83-88. doi: 10.1007/s12253-017-0216-4. Epub 2017 Mar 29.

PMID:
28357685
17.

[Novelties and experience with tyrosine kinase inhibitor therapy in chronic myeloid leukemia].

Gaál-Weisinger J, Mucsi O, Körösmezey G, Szili B, Eid H, Kiss R, Bödör C, Tárkányi I, Nagy Z, Demeter J.

Magy Onkol. 2017 Mar 8;61(1):67-74. Epub 2017 Feb 3. Hungarian.

18.

[Molecular monitoring of myeloid leukemia].

Kiss R, Király AP, Gaál-Weisinger J, Marosvári D, Gángó PA, Demeter J, Bödör C.

Magy Onkol. 2017 Mar 8;61(1):57-66. Epub 2017 Jan 29. Hungarian.

19.

[The role of driver and subclonal mutations in pathogenesis of primary myelofibrosis].

Mózes R, Gángó A, Boha Z, Csomor J, Bödör C.

Magy Onkol. 2017 Mar 8;61(1):36-45. Epub 2016 Apr 13. Hungarian.

20.

[TP53 mutation analysis in chronic lymphocytic leukaemia].

Fésüs V, Marosvári D, Kajtár B, Király PA, Demeter J, Gurbity Pálfi T, Egyed M, Plander M, Farkas P, Mátrai Z, Matolcsy A, Bödör C.

Orv Hetil. 2017 Feb;158(6):220-228. doi: 10.1556/650.2017.30656. Hungarian.

PMID:
28166664
21.

[Chronic myelogenous leukemia: diagnosis and treatment].

Demeter J, Poros A, Bödör C, Horváth L, Masszi T.

Orv Hetil. 2016 Sep;157(37):1459-68. doi: 10.1556/650.2016.30521. Hungarian.

PMID:
27615196
22.

[Novelties in the diagnostics and therapy of hairy cell leukemia].

Sári E, Rajnai H, Dénes K, Bödör C, Csomor J, Körösmezey G, Tárkányi I, Eid H, Nagy Z, Demeter J.

Magy Onkol. 2016 Jun 6;60(2):137-44. Epub 2016 Apr 15. Review. Hungarian.

23.

[The genetic landscape of chronic lymphocytic leukemia].

Marosvári D, Alpár D, Király AP, Rajnai H, Reiniger L, Bödör C.

Magy Onkol. 2016 Jun 6;60(2):118-25. Epub 2016 Feb 6. Review. Hungarian.

24.

[Introduction to the molecular diagnostic methods of oncohematology].

Király AP, Alpár D, Fésüs V, Marosvári D, Matolcsy A, Bödör C.

Magy Onkol. 2016 Jun 6;60(2):88-98. Epub 2016 Feb 15. Review. Hungarian.

25.

Corrigendum: Recurrent mTORC1-activating RRAGC mutations in follicular lymphoma.

Okosun J, Wolfson RL, Wang J, Araf S, Wilkins L, Castellano BM, Escudero-Ibarz L, Seraihi AF, Richter J, Bernhart SH, Efeyan A, Iqbal S, Matthews J, Clear A, Guerra-Assunção JA, Bödör C, Quentmeier H, Mansbridge C, Johnson P, Davies A, Strefford JC, Packham G, Barrans S, Jack A, Du MQ, Calaminici M, Lister TA, Auer R, Montoto S, Gribben JG, Siebert R, Chelala C, Zoncu R, Sabatini DM, Fitzgibbon J.

Nat Genet. 2016 May 27;48(6):700. doi: 10.1038/ng0616-700b. No abstract available.

PMID:
27230687
26.

Increased Lipocalin 2 level may have important role in thrombotic events in patients with polycythemia vera and essential thrombocythemia.

Rajnics P, Kellner Á, Karádi É, Moizs M, Bödör C, Király PA, Marosvári D, Andrikovics H, Egyed M.

Leuk Res. 2016 Sep;48:101-6. doi: 10.1016/j.leukres.2016.04.016. Epub 2016 Apr 28.

PMID:
27161323
27.

Catalog of genetic progression of human cancers: non-Hodgkin lymphoma.

Bödör C, Reiniger L.

Cancer Metastasis Rev. 2016 Mar;35(1):109-27. doi: 10.1007/s10555-016-9608-2. Review.

PMID:
26957091
28.

[Clinical and genetic background of familial myelodysplasia and acute myeloid leukemia].

Király PA, Kállay K, Marosvári D, Benyó G, Szőke A, Csomor J, Bödör C.

Orv Hetil. 2016 Feb 21;157(8):283-9. doi: 10.1556/650.2016.30375. Review. Hungarian.

PMID:
26876264
29.

Recurrent mTORC1-activating RRAGC mutations in follicular lymphoma.

Okosun J, Wolfson RL, Wang J, Araf S, Wilkins L, Castellano BM, Escudero-Ibarz L, Al Seraihi AF, Richter J, Bernhart SH, Efeyan A, Iqbal S, Matthews J, Clear A, Guerra-Assunção JA, Bödör C, Quentmeier H, Mansbridge C, Johnson P, Davies A, Strefford JC, Packham G, Barrans S, Jack A, Du MQ, Calaminici M, Lister TA, Auer R, Montoto S, Gribben JG, Siebert R, Chelala C, Zoncu R, Sabatini DM, Fitzgibbon J.

Nat Genet. 2016 Feb;48(2):183-8. doi: 10.1038/ng.3473. Epub 2015 Dec 21. Erratum in: Nat Genet. 2016 May 27;48(6):700.

30.

Expression of Vascular Endothelial Growth Factor Has a Regulatory Role in Gingival Venules in Experimental Diabetes.

Gyurkovics M, Nagy I, Bodor C, Székely AD, Dinya E, Rosivall L, Lohinai Z.

J Periodontol. 2016 Mar;87(3):e27-34. doi: 10.1902/jop.2015.150410. Epub 2015 Nov 12.

PMID:
26561995
31.

Disease evolution and outcomes in familial AML with germline CEBPA mutations.

Tawana K, Wang J, Renneville A, Bödör C, Hills R, Loveday C, Savic A, Van Delft FW, Treleaven J, Georgiades P, Uglow E, Asou N, Uike N, Debeljak M, Jazbec J, Ancliff P, Gale R, Thomas X, Mialou V, Döhner K, Bullinger L, Mueller B, Pabst T, Stelljes M, Schlegelberger B, Wozniak E, Iqbal S, Okosun J, Araf S, Frank AK, Lauridsen FB, Porse B, Nerlov C, Owen C, Dokal I, Gribben J, Smith M, Preudhomme C, Chelala C, Cavenagh J, Fitzgibbon J.

Blood. 2015 Sep 3;126(10):1214-23. doi: 10.1182/blood-2015-05-647172. Epub 2015 Jul 10.

32.

Low CD23 expression correlates with high CD38 expression and the presence of trisomy 12 in CLL.

Kriston C, Bödör C, Szenthe K, Bánáti F, Bánkuti B, Csernus B, Reiniger L, Csomor J, Matolcsy A, Barna G.

Hematol Oncol. 2017 Mar;35(1):58-63. doi: 10.1002/hon.2244. Epub 2015 Jun 29.

PMID:
26119874
33.

Therapeutic challenge during the long-term follow-up of a patient with indolent systemic mastocytosis with extensive cutaneous involvement.

Marton I, Pósfai É, Borbényi Z, Bödör C, Papp G, Demeter J, Korom I, Varga E, Bata-Csörgő Z.

Eur Rev Med Pharmacol Sci. 2015;19(9):1607-9.

34.

Altered microRNA expression in folliculotropic and transformed mycosis fungoides.

Marosvári D, Téglási V, Csala I, Marschalkó M, Bödör C, Timár B, Csomor J, Hársing J, Reiniger L.

Pathol Oncol Res. 2015 Jul;21(3):821-5. doi: 10.1007/s12253-015-9897-8. Epub 2015 Feb 20.

PMID:
25698383
35.

Treatment of refractory hairy cell leukemia with a BRAF-inhibitor: lessons to be learnt.

Sári E, Nagy ZG, Baghy K, Rajnai H, Bödör C, Csomor J, Barna G, Rudas G, Kovalszky I, Demeter J.

Pathol Oncol Res. 2014 Oct;20(4):973-80. doi: 10.1007/s12253-014-9783-9. Epub 2014 May 3.

PMID:
24789721
36.

LPS-induced delayed preconditioning is mediated by Hsp90 and involves the heat shock response in mouse kidney.

Kaucsár T, Bodor C, Godó M, Szalay C, Révész C, Németh Z, Mózes M, Szénási G, Rosivall L, Sőti C, Hamar P.

PLoS One. 2014 Mar 19;9(3):e92004. doi: 10.1371/journal.pone.0092004. eCollection 2014.

37.

Integrated genomic analysis identifies recurrent mutations and evolution patterns driving the initiation and progression of follicular lymphoma.

Okosun J, Bödör C, Wang J, Araf S, Yang CY, Pan C, Boller S, Cittaro D, Bozek M, Iqbal S, Matthews J, Wrench D, Marzec J, Tawana K, Popov N, O'Riain C, O'Shea D, Carlotti E, Davies A, Lawrie CH, Matolcsy A, Calaminici M, Norton A, Byers RJ, Mein C, Stupka E, Lister TA, Lenz G, Montoto S, Gribben JG, Fan Y, Grosschedl R, Chelala C, Fitzgibbon J.

Nat Genet. 2014 Feb;46(2):176-181. doi: 10.1038/ng.2856. Epub 2013 Dec 22.

38.

Functional analysis of a breast cancer-associated FGFR2 single nucleotide polymorphism using zinc finger mediated genome editing.

Robbez-Masson LJ, Bödör C, Jones JL, Hurst HC, Fitzgibbon J, Hart IR, Grose RP.

PLoS One. 2013 Nov 12;8(11):e78839. doi: 10.1371/journal.pone.0078839. eCollection 2013.

39.

EZH2 mutations are frequent and represent an early event in follicular lymphoma.

Bödör C, Grossmann V, Popov N, Okosun J, O'Riain C, Tan K, Marzec J, Araf S, Wang J, Lee AM, Clear A, Montoto S, Matthews J, Iqbal S, Rajnai H, Rosenwald A, Ott G, Campo E, Rimsza LM, Smeland EB, Chan WC, Braziel RM, Staudt LM, Wright G, Lister TA, Elemento O, Hills R, Gribben JG, Chelala C, Matolcsy A, Kohlmann A, Haferlach T, Gascoyne RD, Fitzgibbon J.

Blood. 2013 Oct 31;122(18):3165-8. doi: 10.1182/blood-2013-04-496893. Epub 2013 Sep 19.

40.

Highly variable clinical manifestations in a large family with a novel GATA2 mutation.

Mutsaers PG, van de Loosdrecht AA, Tawana K, Bödör C, Fitzgibbon J, Menko FH.

Leukemia. 2013 Nov;27(11):2247-8. doi: 10.1038/leu.2013.105. Epub 2013 Apr 8. No abstract available.

PMID:
23563236
41.

GATA2 mutations in sporadic and familial acute myeloid leukaemia patients with CEBPA mutations.

Green CL, Tawana K, Hills RK, Bödör C, Fitzgibbon J, Inglott S, Ancliff P, Burnett AK, Linch DC, Gale RE.

Br J Haematol. 2013 Jun;161(5):701-5. doi: 10.1111/bjh.12317. Epub 2013 Apr 5.

PMID:
23560626
42.

P110α-mediated constitutive PI3K signaling limits the efficacy of p110δ-selective inhibition in mantle cell lymphoma, particularly with multiple relapse.

Iyengar S, Clear A, Bödör C, Maharaj L, Lee A, Calaminici M, Matthews J, Iqbal S, Auer R, Gribben J, Joel S.

Blood. 2013 Mar 21;121(12):2274-84. doi: 10.1182/blood-2012-10-460832. Epub 2013 Jan 22.

43.

Long lasting complete molecular remission after suspending dasatinib treatment in chronic myeloid leukemia.

Gadó K, Matolcsy A, Csomor J, Kicsi D, Bödör C, Domján G.

Exp Hematol Oncol. 2012 Jul 11;1(1):17. doi: 10.1186/2162-3619-1-17.

44.

Microvascular regulatory role and increased expression of vascular endothelial growth factor receptor type 2 in experimental gingivitis.

Gyurkovics M, Lohinai Z, Győrfi A, Bodor C, Székely AD, Dinya E, Rosivall L.

J Periodontal Res. 2013 Apr;48(2):194-202. doi: 10.1111/j.1600-0765.2012.01520.x. Epub 2012 Sep 7.

PMID:
22957787
45.

Enhancer of zeste homologue 2 (EZH2) is a reliable immunohistochemical marker to differentiate malignant and benign hepatic tumors.

Hajósi-Kalcakosz S, Dezső K, Bugyik E, Bödör C, Paku S, Pávai Z, Halász J, Schlachter K, Schaff Z, Nagy P.

Diagn Pathol. 2012 Jul 18;7:86. doi: 10.1186/1746-1596-7-86.

46.

Structural analysis of oval-cell-mediated liver regeneration in rats.

Dezső K, Papp V, Bugyik E, Hegyesi H, Sáfrány G, Bödör C, Nagy P, Paku S.

Hepatology. 2012 Oct;56(4):1457-67. doi: 10.1002/hep.25713. Epub 2012 Jul 30.

PMID:
22419534
47.

EBNA3B-deficient EBV promotes B cell lymphomagenesis in humanized mice and is found in human tumors.

White RE, Rämer PC, Naresh KN, Meixlsperger S, Pinaud L, Rooney C, Savoldo B, Coutinho R, Bödör C, Gribben J, Ibrahim HA, Bower M, Nourse JP, Gandhi MK, Middeldorp J, Cader FZ, Murray P, Münz C, Allday MJ.

J Clin Invest. 2012 Apr;122(4):1487-502. doi: 10.1172/JCI58092. Epub 2012 Mar 12.

48.

Impact of the reactive microenvironment on the bone marrow involvement of follicular lymphoma.

Rajnai H, Bödör C, Balogh Z, Gagyi E, Csomor J, Krenács T, Tóth E, Matolcsy A.

Histopathology. 2012 May;60(6B):E66-75. doi: 10.1111/j.1365-2559.2012.04187.x. Epub 2012 Mar 6.

PMID:
22394030
49.

Germ-line GATA2 p.THR354MET mutation in familial myelodysplastic syndrome with acquired monosomy 7 and ASXL1 mutation demonstrating rapid onset and poor survival.

Bödör C, Renneville A, Smith M, Charazac A, Iqbal S, Etancelin P, Cavenagh J, Barnett MJ, Kramarzová K, Krishnan B, Matolcsy A, Preudhomme C, Fitzgibbon J, Owen C.

Haematologica. 2012 Jun;97(6):890-4. doi: 10.3324/haematol.2011.054361. Epub 2012 Jan 22.

50.

Myelodysplastic syndrome: 2011 and beyond.

Okosun J, Bödör C, Smith M.

Br J Nurs. 2011 Dec 8-2012 Jan 11;20(22):1434. No abstract available.

PMID:
22241492

Supplemental Content

Support Center